bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Tables 2 - 3 from Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Authors: Eng Lawson , Azad Abul Kalam , Habbous Steven , Pang Vincent , Xu Wei , Maitland-van der Zee Anke H. , Savas Sevtap , Mackay Helen J. , Amir Eitan , Liu Geoffrey
Published: April 2023

PDF file, 97K, Supplementary Tables 2-3: These tables summarize in detail, the predictive association of VEGF pathway polymorphisms with drug response/survival on therapy, drug toxicity and survival parameters.
Supplementary Figure S2 from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

Effect of miR-409 overexpression in LNCaP cells. A, miR-409-5p and miR-409-3p levels in LNCaP control cells (LNCaP-C) and LNCaP miR-409 expressing cells (LNCaP-409) measured by qRT-PCR. B, Protein expression of RSU1 in LNCaP-C and LNCaP-409 PCa cells. C, Protein expression of E-cadherin in ARCaP-409 and LNCaP-409 PCa cells compared to their controls, measured by western analysis.
Supplementary Figure S1 from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

A, miR-409-5p and miR-409-3p binding sties in 3`UTR of RSU1 mRNA. B, Effect miR-409-5p mimic binding on 3` UTR of RSU1 luciferase construct, both wild type and mutated construct. Effect of miR-409-5p mimic and miR-409-3p mimic on STAG2 3`UTR luciferase construct measured by luciferase assay.
Supplementary Table 2 from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Authors: Zorniak Michael , Clark Paul A. , Leeper Heather E. , Tipping Matthew D. , Francis David M. , Kozak Kevin R. , Salamat M. Shahriar , Kuo John S.
Published: April 2023

PDF file, 78KB, Antibodies used for immunohistochemical analysis of human glioblastoma stem-like cell induced mouse xenograft tumors and grade IV astrocytoma tissue microarray.
Supplementary Figure 2 from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Authors: Zorniak Michael , Clark Paul A. , Leeper Heather E. , Tipping Matthew D. , Francis David M. , Kozak Kevin R. , Salamat M. Shahriar , Kuo John S.
Published: April 2023

PDF file, 80KB, Differential neural lineage marker expression associate with survivability of GSC-induced xenografts in immunodeficient mice.
Supplementary Figure 1 from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Authors: Zorniak Michael , Clark Paul A. , Leeper Heather E. , Tipping Matthew D. , Francis David M. , Kozak Kevin R. , Salamat M. Shahriar , Kuo John S.
Published: April 2023

PDF file, 327KB, Low and high magnification histology and IHC of differential tumor infiltration in mouse xenografts.
Figure S1 from Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
Authors: Wozniak Agnieszka , Rutkowski Piotr , Schöffski Patrick , Ray-Coquard Isabelle , Hostein Isabelle , Schildhaus Hans-Ulrich , Le Cesne Axel , Bylina Elzbieta , Limon Janusz , Blay Jean-Yves , Siedlecki Janusz A. , Wardelmann Eva , Sciot Raf , Coindre Jean-Michel , Debiec-Rychter Maria
Published: April 2023

Figure S1. Disease free survival grouped according to the presence of KIT ex. 11 mutations: KITdel-inc557/558 vs. other deletions vs. duplications vs. substitutions overall (p<0.0001) (A), in gastric GIST (p<0.0001) (B), non-gastric tumors (p=0.599) (C), and in tumors localized in the stomach, classified as non-high risk (p=0.002) (D). Complete observations are marked with circle (o) and censored one with a cross (+).
CCR Translation for This Article from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Authors: Zorniak Michael , Clark Paul A. , Leeper Heather E. , Tipping Matthew D. , Francis David M. , Kozak Kevin R. , Salamat M. Shahriar , Kuo John S.
Published: April 2023

CCR Translation for This Article from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Table S3 from Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Authors: Whatcott Clifford J. , Diep Caroline H. , Jiang Ping , Watanabe Aprill , LoBello Janine , Sima Chao , Hostetter Galen , Shepard H. Michael , Von Hoff Daniel D. , Han Haiyong
Published: April 2023

Table S3. Univariate Analysis of clinicopathologic factors and patient survival.
Table S2 from Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Authors: Whatcott Clifford J. , Diep Caroline H. , Jiang Ping , Watanabe Aprill , LoBello Janine , Sima Chao , Hostetter Galen , Shepard H. Michael , Von Hoff Daniel D. , Han Haiyong
Published: April 2023

Table S2. Pathological data of 50 pancreatic cancer patients analyzed in our survival analysis.
Supplementary Figure 3 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Authors: Rivera Zeyana , Ferrone Soldano , Wang Xinhui , Jube Sandro , Yang Haining , Pass Harvey I. , Kanodia Shreya , Gaudino Giovanni , Carbone Michele
Published: April 2023

PDF file, 4250K, The interaction between CSPG4 and the extracellular matrix (ECM) promotes MM cell adhesion.
Supplementary Figures S8-9. from Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial
Authors: Yamamoto Hirofumi , Murata Kohei , Fukunaga Mutsumi , Ohnishi Tadashi , Noura Shingo , Miyake Yasuhiro , Kato Takeshi , Ohtsuka Masahisa , Nakamura Yurika , Takemasa Ichiro , Mizushima Tsunekazu , Ikeda Masataka , Ohue Masayuki , Sekimoto Mitsugu , Nezu Riichiro , Matsuura Nariaki , Monden Morito , Doki Yuichiro , Mori Masaki
Published: April 2023

Figure S8: Survival analyses of the entire CEAã€€band-positive group.ã€€ Of the entire CEA band-positive cases, 31 cases eventually received post-operative chemotherapy using HCFU for one year, whereas 41 cases had no treatment. There was no significant difference in 5-year DFS and 5-year OS between the two groups.; Figure S9. Survival curves stratified by High CK19 expression and Low CK19 expression. Survival analyses indicated that the High CK19 group (n=96) had a significantly (A) worse 5-year DFS (P= 0.001), (B) 5-year OS (P= 0.020), and (C) OS (P= 0.014) as compared to the Low CK19 group (n=193). A total of 289 cases with residual preserved RNA were analyzed.
Supplementary Figure 2 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Authors: Rivera Zeyana , Ferrone Soldano , Wang Xinhui , Jube Sandro , Yang Haining , Pass Harvey I. , Kanodia Shreya , Gaudino Giovanni , Carbone Michele
Published: April 2023

PDF file, 2191K, Silencing of CSPG4 expression in MM cells.
Supplementary Table 3 from Targeting Cancer Cells via the Reactive Oxygen Species-Mediated Unfolded Protein Response with a Novel Synthetic Polyphenol Conjugate
Authors: Shin Soon Young , Lee Jong Min , Lee Mi So , Koh Dongsoo , Jung Hyeryoung , Lim Yoongho , Lee Young Han
Published: April 2023

PDF file - 121K, Structures of chalcones and benzoflavones, and their nomenclature.
Supplementary Table 1 from Blocking and Randomization to Improve Molecular Biomarker Discovery
Authors: Qin Li-Xuan , Zhou Qin , Bogomolniy Faina , Villafania Liliana , Olvera Narciso , Cavatore Magali , Satagopan Jaya M. , Begg Colin B. , Levine Douglas A.
Published: April 2023

PDF file - 47KB, List of differentially expressed markers (p<0.01) in the randomized data.
Supplementary Table 2 from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

Trop-2-associated functions driven by Akt-phosphorylation
Supplementary Figure Legends from Blocking and Randomization to Improve Molecular Biomarker Discovery
Authors: Qin Li-Xuan , Zhou Qin , Bogomolniy Faina , Villafania Liliana , Olvera Narciso , Cavatore Magali , Satagopan Jaya M. , Begg Colin B. , Levine Douglas A.
Published: April 2023

PDF file - 51KB
Supplementary Table 1 from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

Proteomic analysis of the Trop-2 signal transduction network
Supplementary Figures 4-6 from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

Supplemental Figure 4: Trop-2-independent cell growth reduction by inhibitors of mTOR, NF-kB and JNK; Supplementary Figure 5: Dose-response curves for signaling pathway inhibitors; Supplementary Figure 6: Correlated expression of Trop-2, phospho-T308 Akt and phospho-S473 Akt in primary breast cancer
Supplementary Figure 3 from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

Trop-2 drives the recruitment of Akt to the cell membrane via its PH domain.
Data Supplement from A Novel KLF4/LDHA Signaling Pathway Regulates Aerobic Glycolysis in and Progression of Pancreatic Cancer
Authors: Shi Min , Cui Jiujie , Du Jiawei , Wei Daoyan , Jia Zhiliang , Zhang Jun , Zhu Zhenggang , Gao Yong , Xie Keping
Published: April 2023

Supplementary Figures 1-5 Legends
Supplementary Table 2 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 60K, Differentially expressed miRNAs in ccRCCs as compared to the matched adjacent normal tissues.
Supplementary material and methods from Elevated Serum Angiopoietin-like Protein 2 Correlates with the Metastatic Properties of Colorectal Cancer: A Serum Biomarker for Early Diagnosis and Recurrence
Authors: Toiyama Yuji , Tanaka Koji , Kitajima Takahito , Shimura Tadanobu , Kawamura Mikio , Kawamoto Aya , Okugawa Yoshinaga , Saigusa Susumu , Hiro Junichiro , Inoue Yasuhiro , Mohri Yasuhiko , Goel Ajay , Kusunoki Masato
Published: April 2023

Supplementary material and methods. Detailed patient characteristics in the validation step, Cell culture condition, 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole (MTT) assay, Anoikis assay, Invasion assay, Wound healing assay,Immunohistochemistry, Enzyme-Linked Immunosorbent Assay (ELISA).
Supplementary Figure 4 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 89K, Overexpression of miR-141 leads to a significant decrease of multiple targets.
Data Supplement from p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Authors: Hardwick Nicola R. , Carroll Mary , Kaltcheva Teodora , Qian Dajun , Lim Dean , Leong Lucille , Chu Peiguo , Kim Joseph , Chao Joseph , Fakih Marwan , Yen Yun , Espenschied Jonathan , Ellenhorn Joshua D. I. , Diamond Don J. , Chung Vincent
Published: April 2023

Supplementary Table 1. Calculation of p53-specific T cell activation
Data Supplement from p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Authors: Hardwick Nicola R. , Carroll Mary , Kaltcheva Teodora , Qian Dajun , Lim Dean , Leong Lucille , Chu Peiguo , Kim Joseph , Chao Joseph , Fakih Marwan , Yen Yun , Espenschied Jonathan , Ellenhorn Joshua D. I. , Diamond Don J. , Chung Vincent
Published: April 2023

Supplementary Figure 2. T cell phenotyping
Supplementary Figure S2 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
Authors: Zhou Ning , Singh Kamini , Mir Maria C. , Parker Yvonne , Lindner Daniel , Dreicer Robert , Ecsedy Jeffrey A. , Zhang Zhongfa , Teh Bin T. , Almasan Alexandru , Hansel Donna E.
Published: April 2023

PDF file - 76 KB, Cell cycle analysis of MLN8237/paclitaxel and MLN8237/gemcitabine combination treatments. Propidium iodide staining with flow cytometry was performed to assess cell cycle changes. Simultaneous MLN8237/paclitaxel and MLN8237/gemcitabine treatments appeared to have little, if any, additional effect on cell cycle arrest compared to MLN8237 alone. Sequential treatments of MLN8237 followed by either paclitaxel or gemcitabine produced the greatest degree of cell cycle derangement.
Supplementary Figure S1 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
Authors: Zhou Ning , Singh Kamini , Mir Maria C. , Parker Yvonne , Lindner Daniel , Dreicer Robert , Ecsedy Jeffrey A. , Zhang Zhongfa , Teh Bin T. , Almasan Alexandru , Hansel Donna E.
Published: April 2023

PDF file - 542 KB, Effects of combination treatments on membrane permeability. T24 cells subjected to combination treatments as described in Figure 5 were stained with trypan blue. Combination treatments resulted in an increased percentage of cells staining positive for trypan blue, most notably in the sequentially dosed combination regimens.
Supplementary Figure Legends from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
Authors: Zhou Ning , Singh Kamini , Mir Maria C. , Parker Yvonne , Lindner Daniel , Dreicer Robert , Ecsedy Jeffrey A. , Zhang Zhongfa , Teh Bin T. , Almasan Alexandru , Hansel Donna E.
Published: April 2023

PDF file - 48 KB
Supplementary Methods from Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Authors: Lin Jie , Sampath Deepak , Nannini Michelle A. , Lee Brian B. , Degtyarev Michael , Oeh Jason , Savage Heidi , Guan Zhengyu , Hong Rebecca , Kassees Robert , Lee Leslie B. , Risom Tyler , Gross Stefan , Liederer Bianca M. , Koeppen Hartmut , Skelton Nicholas J. , Wallin Jeffrey J. , Belvin Marcia , Punnoose Elizabeth , Friedman Lori S. , Lin Kui
Published: April 2023

PDF file - 94K
Supplementary Figures 1 - 5 from Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Authors: Lin Jie , Sampath Deepak , Nannini Michelle A. , Lee Brian B. , Degtyarev Michael , Oeh Jason , Savage Heidi , Guan Zhengyu , Hong Rebecca , Kassees Robert , Lee Leslie B. , Risom Tyler , Gross Stefan , Liederer Bianca M. , Koeppen Hartmut , Skelton Nicholas J. , Wallin Jeffrey J. , Belvin Marcia , Punnoose Elizabeth , Friedman Lori S. , Lin Kui
Published: April 2023

PDF file - 954K, Supplemental Figures: Figure S1. Chemical structure of the Akt inhibitor GDC-0068. Figure S2. Effect of GDC-0068 on cell cycle and apoptotic response on PC-3 and MCF7-neo/HER2 cell lines. Figure S3. Western blot analysis of indicated proteins in isogenic MCF10A cells with and without PTEN knockout in the presence of 20 or 0.2 ng/ml EGF. Figure S4. Representative immunohistochemistry staining images of cleaved caspase-3 in TOV-21G.x1 tumors. Figure S5. Combination effects between GDC-0068 and chemotherapeutic agents in vitro.
Supplementary Table 2 from Rare Cancer Trial Design: Lessons from FDA Approvals
Authors: Gaddipati Himabindu , Liu Ke , Pariser Anne , Pazdur Richard
Published: April 2023

PDF file, 117KB, Postmarketing Safety Issues for Indications with Accelerated Approval vs. Regular Approval.
supplementary Figure 2 from Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Authors: Hu Bo , Yang Xin-Rong , Xu Yang , Sun Yun-Fan , Sun Chao , Guo Wei , Zhang Xin , Wang Wei-Min , Qiu Shuang-Jian , Zhou Jian , Fan Jia
Published: April 2023

Supplementary figure S2. Kaplan-Meier analysis of OS and RFS for (A) NLR and (B) PLR in the training cohort; Predictive ability of the SII was compared with other clinical parameters and the AUCs with 95% CI for TTR in the training (C) and validation cohorts (D) are shown. (*, P<0.05 versus SII).
Supplementary Figure 5 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

PDF file - 28K, Percent of assembled contigs significantly enriched for mutation patterns consistent with evidence of SHM in breast (A, B) and ovarian (C, D) tumors.
Supplementary Figure 4 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

PDF file - 37K, Method of calculating likelihood of enrichment for somatic hypermutation from mRNA-seq reads mapping to BCR segment loci.
Figure S1 from The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models
Authors: Ravi Dashnamoorthy , Bhalla Savita , Gartenhaus Ronald B. , Crombie Jennifer , Kandela Irawati , Sharma Jaya , Mazar Andrew , Evens Andrew M.
Published: April 2023

Figure S1. Western blots of ERK1/2 and SHP1 control experiments for immunoprecipitation.
Supplementary Figure 3 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

PDF file - 57K, Method of calculating BCR sequence diversity from paired-end mRNA-seq reads mapping to BCR segment loci.
Supplementary Figure 2 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

PDF file - 39K, Kaplan-Meier plots, with log-rank p value, of overall or progression-free survival in TCGA breast basal-like and ovarian immunoreactive cancer, respectively.
Supplementary Table 1 from Voxel Level Radiologic–Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer
Authors: Yamin Ghiam , Schenker-Ahmed Natalie M. , Shabaik Ahmed , Adams Dennis , Bartsch Hauke , Kuperman Joshua , White Nathan S. , Rakow-Penner Rebecca A. , McCammack Kevin , Parsons J. Kellogg , Kane Christopher J. , Dale Anders M. , Karow David S.
Published: April 2023

MRI scan parameters for prostate MRI at 3T
Supplementary Methods, Figures 1 - 2 from ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Authors: Lin Fan , de Gooijer Mark C. , Roig Eloy Moreno , Buil Levi C.M. , Christner Susan M. , Beumer Jan H. , Würdinger Thomas , Beijnen Jos H. , van Tellingen Olaf
Published: April 2023

PDF file - 112K, Fig. S1. In vitro transwell assays. Fig. S2. PAR levels by Western blot analysis.
Supplementary Figure S1 from Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome
Authors: Deckers Ivette A.G. , Schouten Leo J. , Van Neste Leander , van Vlodrop Iris J.H. , Soetekouw Patricia M.M.B. , Baldewijns Marcella M.L.L. , Jeschke Jana , Ahuja Nita , Herman James G. , van den Brandt Piet A. , van Engeland Manon
Published: April 2023

Ten-year survival of clear-cell renal cell cancer patients from the population-based series according to CDO1 methylation in patients A) aged {greater than or equal to}55 to <65 years, B) aged {greater than or equal to} 65 to <75 years and C) aged {greater than or equal to}75 years at diagnosis.
Data Supplement from Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Authors: van der Biessen Diane A.J. , Burger Herman , de Bruijn Peter , Lamers Cor H.J. , Naus Nicole , Loferer Hannes , Wiemer Erik A.C. , Mathijssen Ron H.J. , de Jonge Maja J.A.
Published: April 2023

Supplementary Table S1: Overview of CDK inhibitors in development
Data Supplement from Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Authors: van der Biessen Diane A.J. , Burger Herman , de Bruijn Peter , Lamers Cor H.J. , Naus Nicole , Loferer Hannes , Wiemer Erik A.C. , Mathijssen Ron H.J. , de Jonge Maja J.A.
Published: April 2023

Supplementary Figure Legend
Supplementary Table 1 from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Authors: Gros Alena , Turcotte Simon , Wunderlich John R. , Ahmadzadeh Mojgan , Dudley Mark E. , Rosenberg Steven A.
Published: April 2023

PDF file, 51K, Peripheral blood myeloid subsets from melanoma patients (n=7) were stained and sorted and their suppressive activity was tested in a co-culture with autologous T cells activated with anti-CD3/anti-CD28 beads in duplicates. T cell proliferation was assessed by quantifying the percent of T cells that had not diluted the CFSE at day 4 and calculating the percent inhibition of T cell proliferation. Average percent inhibition � SEM are shown. Average of the cumulative data from the 7 patients is also shown.
Supplementary Figure S2 from The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Authors: Krepler Clemens , Chunduru Srinivas K. , Halloran Molly B. , He Xu , Xiao Min , Vultur Adina , Villanueva Jessie , Mitsuuchi Yasuhiro , Neiman Eric M. , Benetatos Christopher , Nathanson Katherine L. , Amaravadi Ravi K. , Pehamberger Hubert , McKinlay Mark , Herlyn Meenhard
Published: April 2023

PDF file - 184 KB, Immunoblots showing two subsets of cell lines: birinapant sensitive and resistant.
Supplementary Figure 2 from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Authors: Gros Alena , Turcotte Simon , Wunderlich John R. , Ahmadzadeh Mojgan , Dudley Mark E. , Rosenberg Steven A.
Published: April 2023

PDF file, 12K, Peripheral blood myeloid cells from healthy donors (n=2) were stained and sorted and their suppressive activity was tested in a co-culture with autologous T cells activated in presence of anti-CD3/anti-CD28 beads in duplicates. T cell proliferation was assessed by quantifying the percent of T cells that had not diluted the CFSE at day 4 and calculating the percent inhibition of T cell proliferation. Average percent inhibition � SEM is shown.
CCR Translation for This Article from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Authors: Gros Alena , Turcotte Simon , Wunderlich John R. , Ahmadzadeh Mojgan , Dudley Mark E. , Rosenberg Steven A.
Published: April 2023

CCR Translation for This Article from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
Supplementary Table 3 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Authors: Fabre Claire , Mimura Naoya , Bobb Kathryn , Kong Sun-Young , Gorgun Güllü , Cirstea Diana , Hu Yiguo , Minami Jiro , Ohguchi Hiroto , Zhang Jie , Meshulam Jeffrey , Carrasco Ruben D. , Tai Yu-Tzu , Richardson Paul G. , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

PDF file, 27K, Table summarizing CI in Dox40 and ANBL6-VR5 cells treated with PBS-1086 and Bortezomib.
Supplementary Figure 1 from PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Patel Hiral , Nguyen Tri , Attkisson Elisa , Grant Steven
Published: April 2023

PDF file - 66K
Supplementary Figure 4 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Authors: Fabre Claire , Mimura Naoya , Bobb Kathryn , Kong Sun-Young , Gorgun Güllü , Cirstea Diana , Hu Yiguo , Minami Jiro , Ohguchi Hiroto , Zhang Jie , Meshulam Jeffrey , Carrasco Ruben D. , Tai Yu-Tzu , Richardson Paul G. , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

PDF file, 119K, Data including MTT results and Western-Blot IκBα, P-IκBα, and p38 in ANBL6-VR5 cells.
Supplementary Figure 1 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Authors: Fabre Claire , Mimura Naoya , Bobb Kathryn , Kong Sun-Young , Gorgun Güllü , Cirstea Diana , Hu Yiguo , Minami Jiro , Ohguchi Hiroto , Zhang Jie , Meshulam Jeffrey , Carrasco Ruben D. , Tai Yu-Tzu , Richardson Paul G. , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

PDF file, 20K, ELISA NF-κB in INA6 and KMS18 cell lines treated with PBS-1086.
Supplementary Table S1 from G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients
Authors: Broselid Stefan , Cheng Benxu , Sjöström Martin , Lövgren Kristina , Klug-De Santiago Heather L.P. , Belting Mattias , Jirström Karin , Malmström Per , Olde Björn , Bendahl Pär-Ola , Hartman Linda , Fernö Mårten , Leeb-Lundberg L.M. Fredrik
Published: April 2023

Association between GPER1 intensity score and various prognostic factors in ER-positive subgroups of cohorts I and II.
Table A3 from Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
Authors: Li Xiao , You Ran , Wang Xinwei , Liu Congxin , Xu Zicheng , Zhou Jin , Yu Bin , Xu Ting , Cai Hongzhou , Zou Qing
Published: April 2023

Table A3 CPM and CBC risk in BRCA1/2 mutation carriers
Supplementary Figure 1 from U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
Authors: Morgan-Linnell Sonia K. , Stewart David J. , Kurzrock Razelle
Published: April 2023

PDF - 122K, Pie chart comparing the classification codes for data audit and for cause inspection.
Supplementary Figure S4 from miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A
Authors: Yin Yuan , Zhang Binbin , Wang Weili , Fei Bojian , Quan Chao , Zhang Jiwei , Song Mingxu , Bian Zehua , Wang Qifeng , Ni Shujuan , Hu Yaling , Mao Yong , Zhou Leyuan , Wang Yugang , Yu Jian , Du Xiang , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S4. Immunohistochemical staining of RAB22A in the CRC and NCT samples. A, RAB22A protein is mainly localised in the cytoplasm. The scores (0, 1, 2 and 3) are based on the intensity of the brown staining. B, RAB22A protein expression was frequently increased in the tumor tissues compared with the matched NCTs (58.5%) in an independent test cohort of 132 CRC cases.
Supplementary Figure S3 from miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A
Authors: Yin Yuan , Zhang Binbin , Wang Weili , Fei Bojian , Quan Chao , Zhang Jiwei , Song Mingxu , Bian Zehua , Wang Qifeng , Ni Shujuan , Hu Yaling , Mao Yong , Zhou Leyuan , Wang Yugang , Yu Jian , Du Xiang , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S3. Ectopic miR-204-5p expression increases the sensitivity of CRC cells to 5-FU and DDP. A, and B, miR-204 overexpression enhanced 5-FU and DDP-induced apoptosis in LoVo (A) and HCT116 (B) cells. Annexin V/PI staining and FACs analysis were performed to detect apoptosis of LoVo and HCT116 cells after administration of 5 μg/mL 5-FU and DDP. The apoptosis levels were determined by the Annexin V positive ratio.
Supplemental Table 2 from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

Number and Measured Sizes of Lung and Liver Metastases by Genotype
Supplemental Figure 4 from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

Col6A1 and Lcn2 promote the migration of PDA cells.
Online Information from A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Authors: Ferrucci Arianna , Moschetta Michele , Frassanito Maria Antonia , Berardi Simona , Catacchio Ivana , Ria Roberto , Racanelli Vito , Caivano Antonella , Solimando Antonio Giovanni , Vergara Daniele , Maffia Michele , Latorre Dominga , Rizzello Antonia , Zito Alfredo , Ditonno Paolo , Maiorano Eugenio , Ribatti Domenico , Vacca Angelo
Published: April 2023

Online Information
Supplementary Figure 1 from Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases
Authors: Guidetti Anna , Carlo-Stella Carmelo , Locatelli Silvia L. , Malorni Walter , Mortarini Roberta , Viviani Simonetta , Russo Domenico , Marchianò Alfonso , Sorasio Roberto , Dodero Anna , Farina Lucia , Giordano Laura , Di Nicola Massimo , Anichini Andrea , Corradini Paolo , Gianni Alessandro M.
Published: April 2023

Supplementary Figure 1. Represents CD30 serum levels at various time during the therapy in 22 patients
Supplementary Figure 2 from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Authors: Giuliano Mario , Hu Huizhong , Wang Yen-Chao , Fu Xiaoyong , Nardone Agostina , Herrera Sabrina , Mao Sufeng , Contreras Alejandro , Gutierrez Carolina , Wang Tao , Hilsenbeck Susan G. , De Angelis Carmine , Wang Nicholas J. , Heiser Laura M. , Gray Joe W. , Lopez-Tarruella Sara , Pavlick Anne C. , Trivedi Meghana V. , Chamness Gary C. , Chang Jenny C. , Osborne C. Kent , Rimawi Mothaffar F. , Schiff Rachel
Published: April 2023

Supplementary Figure 2. ER expression changes upon neoadjuvant treatment with trastuzumab
Supplementary Figure 1 from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Authors: Giuliano Mario , Hu Huizhong , Wang Yen-Chao , Fu Xiaoyong , Nardone Agostina , Herrera Sabrina , Mao Sufeng , Contreras Alejandro , Gutierrez Carolina , Wang Tao , Hilsenbeck Susan G. , De Angelis Carmine , Wang Nicholas J. , Heiser Laura M. , Gray Joe W. , Lopez-Tarruella Sara , Pavlick Anne C. , Trivedi Meghana V. , Chamness Gary C. , Chang Jenny C. , Osborne C. Kent , Rimawi Mothaffar F. , Schiff Rachel
Published: April 2023

Supplementary Figure 1. Lapatinib clinical trial scheme
Supplemental Materials, Figures S1-6, Tables S1-4 from Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer
Authors: Bruun Jarle , Kolberg Matthias , Ahlquist Terje C. , Røyrvik Ellen C. , Nome Torfinn , Leithe Edward , Lind Guro E. , Merok Marianne A. , Rognum Torleiv O. , Bjørkøy Geir , Johansen Terje , Lindblom Annika , Sun Xiao-Feng , Svindland Aud , Liestøl Knut , Nesbakken Arild , Skotheim Rolf I. , Lothe Ragnhild A.
Published: April 2023

Supplemental Materials, Figures S1-6, Tables S1-4. Fig. S1. Flow diagram for inclusion of patients in the study. Fig. S2. RNA secondary structure analysis of the 5'UTR RCC2 mutation compared to wild type. Fig. S3. Vector construction overview. Fig. S4. Morphological changes in actin fiber patterns following depletion of RCC2 protein in HCT15 cells. Fig. S5. Subgroup analyses of in situ protein expression of RCC2 for a consecutive CRC series. Fig. S6. Representative electropherograms from fragment analysis of the 5'UTR RCC2 mutation. Table S1. Statistics for relevant parameters for the test series (n = 37). Table S2. Statistics for relevant parameters for the validation series (n = 122). Table S3. Statistics for relevant parameters for the validation series (n = 60, R0 patients). Table S4. Primer and PCR details.
Supplementary Figures 1 - 8 from A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma
Authors: Nadal Ernest , Zhong Jinjie , Lin Jules , Reddy Rishindra M. , Ramnath Nithya , Orringer Mark B. , Chang Andrew C. , Beer David G. , Chen Guoan
Published: April 2023

PDF file - 1289KB, Fig S1- Box plots of the risk score values in the training and test set. Fig S2- SAM plot of 10 lung AC versus 10 matched nonmalignant lung samples. Fig S3- Pathway enrichment analysis based on predicted genes targeted by top 10 miRs discriminating lung AC vs. nonmalignant lung. Fig S4- Hierarchical clustering based on miR expression in 91 lung ACs, without including nonmalignant samples. Fig S5- Hierarchical clustering based on 306 most variable expressed miRs in 474 lung ACs from TCGA-Lung Adenocarcinoma cohort. Fig S6- Box plots of average expression of genes involved in Notch pathway, c-Myc targets, embryonic stem-cell signature among the 3 miR clusters in 51 lung AC. Fig S7- Kaplan-Meier plots of OS in the training set for 3 miRs encoded at the 14q32 region and selected for validation. Fig S8- Scatterplot matrix showing the correlation between 21 miRs encoded at 14q32.
S6: MDM2, MDM4 and p53 protein level in the GBM cell lines of cohort #1 as determined by western blot from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Authors: Verreault Maite , Schmitt Charlotte , Goldwirt Lauriane , Pelton Kristine , Haidar Samer , Levasseur Camille , Guehennec Jeremy , Knoff David , Labussière Marianne , Marie Yannick , Ligon Azra H. , Mokhtari Karima , Hoang-Xuan Khê , Sanson Marc , Alexander Brian M. , Wen Patrick Y. , Delattre Jean-Yves , Ligon Keith L. , Idbaih Ahmed
Published: April 2023

S6: MDM2, MDM4 and p53 protein level in the GBM cell lines of cohort #1 as determined by western blot
Supplementary Figure 5 from Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Authors: Cook Katherine L. , Wärri Anni , Soto-Pantoja David R. , Clarke Pamela AG. , Cruz M. Idalia , Zwart Alan , Clarke Robert
Published: April 2023

Circulating mouse cytokine and chemokine involvement. A. Circulated levels of MCP-1, RANTES, Eotaxin, KC, MDC, TARC, and TCA3 were measured by ELISA from mouse plasma. n=3-6
S1: Genetic landscape of MDM2/TP53 pathway. from Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Authors: Verreault Maite , Schmitt Charlotte , Goldwirt Lauriane , Pelton Kristine , Haidar Samer , Levasseur Camille , Guehennec Jeremy , Knoff David , Labussière Marianne , Marie Yannick , Ligon Azra H. , Mokhtari Karima , Hoang-Xuan Khê , Sanson Marc , Alexander Brian M. , Wen Patrick Y. , Delattre Jean-Yves , Ligon Keith L. , Idbaih Ahmed
Published: April 2023

A) Genetic status of TP53, MDM2 and MDM4 from TCGA 2013 dataset. B) MDM2 mRNA expression level in relation to MDM2 copy number alterations from TCGA 2013 dataset.
Supplemental Figures and Tables from Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
Authors: Varadan Vinay , Gilmore Hannah , Miskimen Kristy L.S. , Tuck David , Parsai Shikha , Awadallah Amad , Krop Ian E. , Winer Eric P. , Bossuyt Veerle , Somlo George , Abu-Khalaf Maysa M. , Fenton Mary Anne , Sikov William , Harris Lyndsay N.
Published: April 2023

Supplemental Figure 1. Consort Diagram 03-311. Supplemental Figure 2. Consort Diagram 211B. Supplemental Figure 3. Subtype-specific changes in Immune Index upon brief-exposure to nab-paclitaxel in the 211B trial. Supplemental Figure 4. Evaluation of the Immune Index upon brief-exposure to trastuzumab in the 03-311 and 211B trials according to ER/PR status. Supplemental Figure 5. Evaluation of the Immune Index upon brief-exposure to nab-paclitaxel in the 211B trial according to ER/PR status. Supplemental Figure 6. Correlation between Immune Index and tumor content. Supplemental Figure 7. Association of CD4+ Th1 and Treg signatures with response. Supplemental Table 1. Immune Index genes discriminative of response at the post-exposure timepoint in the discovery (03-311) and validation (211B) datasets. Supplemental Table 2. Immune cell subset signatures discriminative of response at baseline and post-exposure timepoints in the discovery (03-311) and validation (211B) datasets. Supplemental Table 3. CD8+ T-cell cytolytic activity genes discriminative of response at the post-exposure timepoint in the discovery (03-311) and validation (211B) datasets.
Supplemental Figure 4 from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
Authors: Gustafson Michael P. , Lin Yi , Bleeker Jonathan S. , Warad Deepti , Tollefson Matthew K. , Crispen Paul L. , Bulur Peggy A. , Harrington Susan M. , Laborde Rebecca R. , Gastineau Dennis A. , Leibovich Bradley C. , Cheville John C. , Kwon Eugene D. , Dietz Allan B.
Published: April 2023

Supplemental Figure 4. Co-cultures of CD14+ monocytes and other renal cell lines.
Supplemental Figure 2 from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
Authors: Gustafson Michael P. , Lin Yi , Bleeker Jonathan S. , Warad Deepti , Tollefson Matthew K. , Crispen Paul L. , Bulur Peggy A. , Harrington Susan M. , Laborde Rebecca R. , Gastineau Dennis A. , Leibovich Bradley C. , Cheville John C. , Kwon Eugene D. , Dietz Allan B.
Published: April 2023

Supplemental Figure 2. Gating strategies for myeloid cells.
Supplementary Figure Legends from Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Authors: Wainwright Derek A. , Chang Alan L. , Dey Mahua , Balyasnikova Irina V. , Kim Chung Kwon , Tobias Alex , Cheng Yu , Kim Julius W. , Qiao Jian , Zhang Lingjiao , Han Yu , Lesniak Maciej S.
Published: April 2023

PDF file - 72KB
Supplementary Figure 1 from Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Authors: Wainwright Derek A. , Chang Alan L. , Dey Mahua , Balyasnikova Irina V. , Kim Chung Kwon , Tobias Alex , Cheng Yu , Kim Julius W. , Qiao Jian , Zhang Lingjiao , Han Yu , Lesniak Maciej S.
Published: April 2023

PDF file - 1742KB, Supplementary Figure 1. The inhibition of CTLA-4, PD-L1 and IDO at 1 week postintracranial injection (wp-ic.) changes the expression of PD-1 and CTLA-4 on brain tumorinfiltrating T cells.
Supplementary Table 2 from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

DHT regulated pathways
Supplemental Fig.1 from miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Authors: Yang Yijun , Li Fei , Saha Manujendra N. , Abdi Jahangir , Qiu Lugui , Chang Hong
Published: April 2023

Supplemental Fig.1. Ideogram showing the chromosome 1p12-1p21 minimum deletion region, and location of five miRNAs on cytogenetic bands
Supplementary Materials and Methods, Tables ST1-13 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Authors: GuhaThakurta Debraj , Sheikh Nadeem A. , Fan Li-Qun , Kandadi Harini , Meagher T. Craig , Hall Simon J. , Kantoff Philip W. , Higano Celestia S. , Small Eric J. , Gardner Thomas A. , Bailey Kate , Vu Tuyen , DeVries Todd , Whitmore James B. , Frohlich Mark W. , Trager James B. , Drake Charles G.
Published: April 2023

Supplementary materials and Methods, Tables ST1-13. Table ST1: Baseline clinical characteristics of patients in IMPACT Table ST2: Baseline clinical characteristics of patients in ProACT. Table ST3: Increase in levels of IgG against candidate antigens at weeks 2 and 22 in IMPACT as measured with ProtoArray Table ST4: Protein reagents used in Luminex xMAP assays. Table ST5: Overlap of the number of patients who were IgG responders to different antigens at week 10 after treatment in the sipuleucel-T arm of IMPACT. Table ST6: Evaluation of IgG responses to candidate antigens at week 12 in ProACT using Luminex xMAP. Table ST7: Association of post-treatment changes in serum levels of IgG at week 10 with OS in the sipuleucel-T arm of IMPACT. Table ST8: Comparison of OS in sipuleucel-T-treated IgG responders and IgG non-responders at week 10 with that in control patients in IMPACT. Table ST9: Evaluation of IgG responses against candidate antigens at weeks 2 and 22 in IMPACT using Luminex xMAP. Table ST10: Assessment of IgG responses against candidate antigens at weeks 4 and 20 in ProACT using Luminex xMAP. Table ST11: Overlap of the number of sipuleucel-T-treated patients who were IgG responders to antigens across the post-treatment time points in IMPACT Table ST12: Association of changes in serum IgG levels with OS at week 2 or 22 in the sipuleucel-T arm of IMPACT. Table ST13: Comparison of OS in sipuleucel-T-treated IgG responders and IgG non-responders with that in control patients at weeks 2 and 22 in IMPACT.
Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Methods, including numbered supplementary methods figures and figure legends
Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Figure S3. pNBS1 staining post-combination treatment is limited to tumor cells.
Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Authors: LoRusso Patricia M. , Li Jing , Burger Angelika , Heilbrun Lance K. , Sausville Edward A. , Boerner Scott A. , Smith Daryn , Pilat Mary Jo , Zhang Jie , Tolaney Sara M. , Cleary James M. , Chen Alice P. , Rubinstein Lawrence , Boerner Julie L. , Bowditch Adam , Cai Dongpo , Bell Tracy , Wolanski Andrew , Marrero Allison M. , Zhang Yiping , Ji Jiuping , Ferry-Galow Katherine , Kinders Robert J. , Parchment Ralph E. , Shapiro Geoffrey I.
Published: April 2023

Supplementary Figure S1. Study schema.
Appendix 2: Supplemental Tables 1-3 and Supplemental Figure 1 from Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Authors: Xia Jing , Trock Bruce J. , Gulati Roman , Mallinger Leslie , Cooperberg Matthew R. , Carroll Peter R. , Carter H. Ballentine , Etzioni Ruth
Published: April 2023

Calculation of the hazard ratio for other-cause death. Supplemental Table 1: SEER relative survival table for localized prostate cancer cases diagnosed between 1994 and 2007. Supplemental Table 2: SEER cause-specific survival table for localized prostate cancer cases diagnosed between 1994 and 2007. Supplemental Table 3: SEER observed interval survival and expected interval survival for localized prostate cancer cases diagnosed between 1994 and 2007. Supplemental Figure 1: Hazard ratios of other-cause death among localized prostate cancer patients diagnosed between 1994 and 2007 in SEER relative to standard US life tables by year after diagnosis.
Supplementary Figure 2 from Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
Authors: Gross Neil D. , Bauman Julie E. , Gooding William E. , Denq William , Thomas Sufi M. , Wang Lin , Chiosea Simion , Hood Brian L. , Flint Melanie S. , Sun Mai , Conrads Thomas P. , Ferris Robert L. , Johnson Jonas T. , Kim Seungwon , Argiris Athanassios , Wirth Lori , Nikiforova Marina N. , Siegfried Jill M. , Grandis Jennifer R.
Published: April 2023

PDF file - 148KB, Exploratory Baseline Analytes.